Evolent Health Inc. (EVH) Receives Average Rating of “Buy” from Analysts
Shares of Evolent Health Inc. (NYSE:EVH) have been given a consensus rating of “Buy” by the seven analysts that are covering the firm. Seven analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $26.20.
EVH has been the topic of a number of recent analyst reports. Zacks Investment Research raised Evolent Health from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a report on Tuesday, October 11th. Jefferies Group set a $28.00 price objective on Evolent Health and gave the stock a “buy” rating in a report on Tuesday, October 4th. Leerink Swann reaffirmed a “buy” rating on shares of Evolent Health in a report on Wednesday, October 5th. Canaccord Genuity reaffirmed a “buy” rating and set a $30.00 price objective on shares of Evolent Health in a report on Wednesday, July 13th. Finally, FBR & Co upped their target price on Evolent Health from $24.00 to $26.00 and gave the company an “outperform” rating in a report on Friday, August 5th.
In other news, major shareholder Board Co Advisory sold 1,936,529 shares of the company’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $22.50, for a total value of $43,571,902.50. Following the sale, the insider now directly owns 4,445,879 shares in the company, valued at $100,032,277.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Jonathan Weinberg sold 10,339 shares of the company’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $21.54, for a total value of $222,702.06. Following the completion of the sale, the general counsel now owns 76,245 shares in the company, valued at $1,642,317.30. The disclosure for this sale can be found here. 8.85% of the stock is owned by insiders.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/evolent-health-inc-evh-receives-average-rating-of-buy-from-analysts.html
Hedge funds have recently modified their holdings of the stock. Ameriprise Financial Inc. bought a new stake in shares of Evolent Health during the second quarter valued at about $1,565,000. Blair William & Co. IL increased its stake in shares of Evolent Health by 205.5% in the second quarter. Blair William & Co. IL now owns 341,570 shares of the company’s stock valued at $6,558,000 after buying an additional 229,748 shares in the last quarter. EAM Investors LLC bought a new stake in shares of Evolent Health during the second quarter valued at about $3,971,000. Emerald Acquisition Ltd. bought a new stake in shares of Evolent Health during the second quarter valued at about $1,301,000. Finally, Swiss National Bank increased its stake in shares of Evolent Health by 90.2% in the second quarter. Swiss National Bank now owns 32,900 shares of the company’s stock valued at $632,000 after buying an additional 15,600 shares in the last quarter. Institutional investors and hedge funds own 39.27% of the company’s stock.
Shares of Evolent Health (NYSE:EVH) traded up 2.68% during mid-day trading on Tuesday, hitting $23.36. 131,656 shares of the company were exchanged. The company’s market capitalization is $1.41 billion. Evolent Health has a 52 week low of $8.14 and a 52 week high of $26.84. The company has a 50 day moving average of $23.85 and a 200 day moving average of $19.04.
Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.04. Evolent Health had a negative return on equity of 5.04% and a negative net margin of 76.55%. The firm had revenue of $56.50 million for the quarter, compared to analyst estimates of $51.96 million. During the same quarter in the prior year, the company posted ($0.95) earnings per share. Evolent Health’s quarterly revenue was up 443.3% on a year-over-year basis. Equities analysts anticipate that Evolent Health will post ($0.54) earnings per share for the current year.
Evolent Health Company Profile
Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.
Receive News & Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.